CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		10 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Nov. 09, 2023	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (34,223,000)	$ (81,966,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,551,000	6,035,000
Amortization of inventory step-up	0	2,537,000
Allowance for credit losses and inventory reserves	262,000	31,000
Share-based compensation	25,577,000	11,395,000
Amortization of discount and cost of issuance of debt	250,000	259,000
Loss from change in fair value of warrants	0	47,332,000	$ 7,066,000
(Gain) loss from change in fair value of contingent considerations and acquisition-related holdbacks	(15,359,000)	1,630,000
Loss from change in fair value of currency forward contract	552,000	0
Deferred tax liabilities	0	(3,716,000)
Amortization of right-of-use assets	822,000	525,000
Changes in operating assets and liabilities:
Accounts receivable	11,752,000	4,823,000
Inventory	(1,051,000)	(9,973,000)
Accounts payable	(414,000)	(2,937,000)
Accrued expenses and other current liabilities	(4,429,000)	(2,085,000)
Accrued payroll liabilities	454,000	269,000
Prepaid and other current assets	(1,816,000)	(5,627,000)
Operating lease liabilities	(824,000)	(453,000)
Other long-term liabilities	(453,000)	(964,000)
Net cash used in operating activities	(9,349,000)	(32,885,000)
Cash flows from investing activities:
Purchases of property and equipment	(2,317,000)	(3,199,000)
Business combinations, net of cash acquired	(3,200,000)	(98,429,000)
Net cash used in investing activities	(5,517,000)	(101,628,000)
Cash flows from financing activities:
Proceeds from issuance of common stock/At-the-market offering	0	34,946,000
Offering costs for the issuance of common stock/At-the-market offering	0	(752,000)
Proceeds from issuance of short-term debt obligations	10,740,000	747,000
Issuance costs on line of credit	(50,000)	0
Payments on debt obligations	(1,493,000)	(11,825,000)
Payments on financed software	(2,341,000)	(2,069,000)
Proceeds from exercise of stock options	24,000	19,000
Net cash provided by financing activities	6,880,000	21,066,000
Effect of exchange rate changes on cash and cash equivalents	4,482,000	(1,034,000)
Net decrease in cash and cash equivalents	(3,504,000)	(114,481,000)
Cash, cash equivalents and restricted cash at beginning of period	151,678,000	321,879,000	$ 321,879,000
Cash, cash equivalents and restricted cash at end of period	148,174,000	207,398,000
Reconciliation of amounts on condensed consolidated balance sheet:
Cash and cash equivalents	138,174,000	207,398,000		$ 151,678,000
Restricted cash	10,000,000			0
Total cash, cash equivalents and restricted cash	148,174,000	207,398,000		$ 151,678,000
Supplemental disclosure of cash flow information:
Cash paid for interest	70,000	88,000
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	(890,000)	348,000
Fair value of common stock issued for business combination	0	85,391,000
Fair value of common stock issuable for business combination	0	20,979,000
Contingent consideration for business combination	4,599,000	73,047,000
Accrual for purchase consideration for business combination	1,300,000	4,264,000
Fair value of common stock issued for investment in Expedera	$ 3,428,000	$ 0